搜索结果: 'methocult media formulations for human hematopoietic cells serum containing'

STEMCELL Submits Drug Master File for mTeSR™1, the Most Widely Published Cell Culture Medium for Human Pluripotent Stem Cells STEMCELL Technologies announced it has filed a Type II Drug Master File (DMF) to the Food and Drug Administration (FDA) for the Cellular Therapy Ancillary Material mTeSR™1 and has been issued DMF# 18339
New Video: Untouched cells in one step with RosetteSep™ STEMCELL Technologies is proud to present an exciting new video showcasing RosetteSep™, a one-step cell separation procedure by negative selection
Human Pluripotent Stem Cell and Organoid Workshop A comprehensive 3 day workshop on methods to maintain human stem cells in culture, and the directed differentiation of these cells to either definitive endoderm or neuronal progenitor cells. We will also cover generation and support of mouse organoid cultures from intestinal crypts.
Frozen Bone Marrow Proficiency Testing Program Evaluate your ability to perform all steps of the CFU assay. Participants are provided with a cell sample, MethoCult™ medium, additional reagents and supplies, and detailed instructions. The results from all participants are analyzed and compared to the cohort mean.
Lunch & Learn with Hematopoietic Experts
Human Airway Epithelial Cells Training
STEMCELL Technologies Celebrates 30 Years with Unprecedented Annual Growth
STEMCELL Launches Novel Cell-Engineering CellPore™ Transfection System
GE Healthcare expands cell therapy portfolio with license of STEMCELL Technologies’ T-Cell reagents Exclusive licensing agreement will provide cGMP grade reagents to further enable development and manufacturing of cellular immunotherapies
Pluripotent Stem Cell Training: Reprogramming, Maintenance and Differentiation of hPSCs Course Learn the complete workflow to successfully derive and maintain high-quality human induced pluripotent stem (hiPS) cells and the protocols for their differentiation towards multiple cell types.
ENKAM Pharmaceuticals A/S Commercial Partnership with STEMCELL Technologies Inc ENKAM Pharmaceuticals A/S (ENKAM), a privately held Danish biopharmaceutical development company focused on cancer and central nervous system disorders, is pleased to announce that it has signed a licensing and development agreement with STEMCELL Technologies Inc.
STEMCELL Technologies Inc. Obtains License from iPS Academia Japan for Induced Pluripotent Stem Cell Technologies STEMCELL Technologies has signed a patent license agreement with iPS Academia Japan, Inc. to license and commercialize iPS Academia Japan, Inc.'s patented technologies for induced pluripotent stem cell (iPS cell) research